In his role on the SAB of NewcelX, Prof. Shefner will provide strategic guidance on the Company's programs in ALS, including ...

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced that its Board ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Call her Dr. McCord. The post RHONY Alum Alex McCord Shares Huge Education Update: ‘It’s Done!’ appeared first on Reality Tea ...

Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; ...

Jan Schellens is a medical oncologist and clinical pharmacologist by training, he previously served as staff member of the Department of Medical Oncology, as Head of the Department of Clinical ...

Sonoma Biotherapeutics Inc. has appointed Stephen Dilly, former President and CEO of Codexis Inc., and current Chair of the ...

The Foundation Fighting Blindness has allowed public open access to de-identified 4-year data from individuals participating ...

NewcelX ( ($NCEL) ) has shared an announcement. On November 17, 2025, NewcelX Ltd. announced the appointment of Prof. Jeremy Shefner, MD, PhD, to ...

A new study led by Yale's Jennifer Miller, PhD, found that medicines are not physically accessible in many of the countries where they are tested for FDA approval.

The ongoing EPIC clinical trial is the first randomized head-to-head comparison of two neonatal Fc receptor (FcRn)-targeting ...